Literature DB >> 26089010

Frequency of Attainment of Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol Goals in Cardiovascular Clinical Practice (from the National Cardiovascular Data Registry PINNACLE Registry).

Sarah A Spinler1, Mark J Cziraky2, Vincent J Willey2, Fengming Tang3, Thomas M Maddox4, Tyan Thomas5, Gladys G Dueñas5, Salim S Virani6.   

Abstract

Studies have found that non-high-density lipoprotein cholesterol (non-HDL-C) is a superior marker for coronary heart disease compared to low-density lipoprotein cholesterol (LDL-C). Little is known about achievement of non-HDL-C goals outside clinical trials. Within a population of 146,064 patients with dyslipidemia in the PINNACLE Registry and a subgroup of 36,188 patients with diabetes mellitus (DM), we examined the proportion of patients and patient characteristics associated with having LDL-C, non-HDL-C, and both LDL-C and non-HDL-C levels at National Cholesterol Education Program goals. LDL-C, non-HDL-C, and both LDL-C and non-HDL-C goals in the overall cohort were achieved by 73%, 73.4%, and 68.9% patients, respectively. Significant predictors of meeting all 3 goals were age, male gender, statin, nonstatin, and combined statin plus nonstatin use. Patients with co-morbidities of hypertension, previous stroke or transient ischemic attack, peripheral arterial disease, myocardial infarction, and smoking were less likely to have LDL-C, non-HDL-C, and both LDL-C and non-HDL-C levels at National Cholesterol Education Program goal. In the overall cohort, patients with DM were less likely to meet non-HDL-C and both LDL-C and non-HDL-C goals. In the subgroup of patients with DM, predictors of meeting lipid goals were similar to the overall cohort. In conclusion, these data suggest contemporary treatment patterns by cardiologists successfully achieve lipid goals in most patients. Younger, female patients and those with atherosclerotic cardiovascular disease and risk factors, such as hypertension and DM, are less likely to achieve goals and may require more careful follow-up after statin initiation. Both LDL-C and non-HDL-C goals are achieved in <70% of patients, suggesting room for improvement if a goal-targeted individualized strategy is adopted.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26089010     DOI: 10.1016/j.amjcard.2015.05.011

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

Review 1.  Impact of Conventional Stroke Risk Factors on Stroke in Women: An Update.

Authors:  Tracy E Madsen; Virginia J Howard; Monik Jiménez; Kathryn M Rexrode; Maria Czarina Acelajado; Dawn Kleindorfer; Seemant Chaturvedi
Journal:  Stroke       Date:  2018-02-08       Impact factor: 7.914

Review 2.  Importance of sex and gender in ischaemic stroke and carotid atherosclerotic disease.

Authors:  Karina Gasbarrino; Diana Di Iorio; Stella S Daskalopoulou
Journal:  Eur Heart J       Date:  2022-02-10       Impact factor: 29.983

Review 3.  The gut microbiome, diet, and links to cardiometabolic and chronic disorders.

Authors:  Judith Aron-Wisnewsky; Karine Clément
Journal:  Nat Rev Nephrol       Date:  2015-11-30       Impact factor: 28.314

Review 4.  The Role of the Gut Microbiota in the Development of Ischemic Stroke.

Authors:  Jinchen Wang; Hongfei Zhang; Jianying He; Xiaoxing Xiong
Journal:  Front Immunol       Date:  2022-03-28       Impact factor: 7.561

Review 5.  Unmet Needs in LDL-C Lowering: When Statins Won't Do!

Authors:  Stephan Krähenbühl; Ivana Pavik-Mezzour; Arnold von Eckardstein
Journal:  Drugs       Date:  2016-08       Impact factor: 9.546

6.  Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets' attainment in subjects with and without type 2 diabetes.

Authors:  Mario Luca Morieri; Valentina Perrone; Chiara Veronesi; Luca Degli Esposti; Margherita Andretta; Mario Plebani; Gian Paolo Fadini; Saula Vigili de Kreutzenberg; Angelo Avogaro
Journal:  Cardiovasc Diabetol       Date:  2021-07-16       Impact factor: 9.951

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.